Back to Results

RVL Pharmaceuticals PLC (RVLPQ)

RVL Pharmaceuticals plc is a specialty pharmaceutical company with operations in the United States, Argentina, and Hungary. The company develops and commercializes medicines aimed at underserved patient groups, with an emphasis on the ocular and medical aesthetics areas. Its commercial product includes Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution used to treat acquired blepharoptosis, or low-lying eyelid, in adults. RVL Pharmaceuticals was previously known as Osmotica Pharmaceuticals plc and adopted its current name in January 2022. The company is headquartered in Bridgewater, New Jersey. Its common stock is listed on OTC Markets under the symbol RVLP.Q.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap
OTC-RVLP.Q
Not available
Not available
Not available
Fair
0.0%
November 13, 2026
0.111 K
Valuation • Fair Value

RVL Pharmaceuticals PLC (OTC-RVLP.Q) Fair Value by Valuation Model

No usable valuation estimate is currently available for RVL Pharmaceuticals PLC (OTC-RVLP.Q); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for RVL Pharmaceuticals PLC (OTC-RVLP.Q). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for RVL Pharmaceuticals PLC (OTC-RVLP.Q)

Review the profitability and growth indicators currently supported by the latest data.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review RVL Pharmaceuticals PLC (OTC-RVLP.Q) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for RVL Pharmaceuticals PLC (OTC-RVLP.Q)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for RVL Pharmaceuticals PLC (OTC-RVLP.Q). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for RVL Pharmaceuticals PLC (OTC-RVLP.Q)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

20

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for RVL Pharmaceuticals PLC (OTC-RVLP.Q), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for RVL Pharmaceuticals PLC (OTC-RVLP.Q) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for RVL Pharmaceuticals PLC (OTC-RVLP.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for RVL Pharmaceuticals PLC (OTC-RVLP.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for RVL Pharmaceuticals PLC (OTC-RVLP.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for RVL Pharmaceuticals PLC (OTC-RVLP.Q) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

RVL Pharmaceuticals PLC (OTC-RVLP.Q) Stock FAQ

Data-supported answers about RVL Pharmaceuticals PLC (OTC-RVLP.Q), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Fair
Current financial-health read

A reliable fair value estimate is not currently available for RVL Pharmaceuticals PLC (OTC-RVLP.Q). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for RVL Pharmaceuticals PLC (OTC-RVLP.Q) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for RVL Pharmaceuticals PLC (OTC-RVLP.Q) is November 13, 2026.

The latest available data indicates no current dividend yield for RVL Pharmaceuticals PLC (OTC-RVLP.Q).

The current market capitalization listed for RVL Pharmaceuticals PLC is 0.111 K.

The ticker symbol for RVL Pharmaceuticals PLC is OTC-RVLP.Q, and the stock is listed on OTC Markets.

RVL Pharmaceuticals PLC (OTC-RVLP.Q) is listed on OTC Markets.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,215.6 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 655.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.2 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 310 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 179.5 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 170.3 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 129 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 113.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 69.723 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 48.75 B
HLN NYSE HALEON PLC ADR Fair Value Undervalued Market Cap 40.368 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 38.751 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.93 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 21.789 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Undervalued Market Cap 14.59 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 11.996 B
ELAN NYSE Elanco Animal Health Fair Value Overvalued Market Cap 11.831 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 7.834 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 6.827 B